A randomized control trial of isoniazid to prevent tuberculosis in kidney transplant recipients living in an endemic area

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200716001

Enrollment

150

Registered

2020-07-16

Start date

2020-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis Immunocompromised host Mortality prevention&#44

Interventions

Isoniazid 300 mg oral daily for 9 months,Placebo oral daily for 9 months

Experimental Drug,Placebo Comparator No treatment

Isoniazid,Placebo

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: Adult kidney transplant recipients

Exclusion criteria

Exclusion criteria: Deny participation Active TB at the time of enrollement Allergic to isoniazid

Design outcomes

Primary

Measure	Time frame
Active TB 9 months Closed monitoring	—

Secondary

Measure	Time frame
INH-resistant TB 9 months Closed monitoring	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital, Mahidol University

jackrapong.brm@mahidol.ac.th6622011851

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026